Author Interviews, Infections, Nature, NYU/NYMC / 25.02.2026

[caption id="attachment_72626" align="aligncenter" width="500"]C. auris- CDC image.jpg Candida auris CDC Image[/caption] MedicalResearch.com Interview with: [caption id="attachment_72627" align="alignleft" width="200"]Vishnu Chaturvedi, Ph.D.Professor of Pathology, Microbiology, and Immunology and of Medicine New York Medical College Vishnu Chaturvedi, Ph.D.[/caption] Vishnu Chaturvedi, Ph.D. Professor of Pathology, Microbiology, and Immunology and of Medicine New York Medical College MedicalResearch.com: What is the background for this study? Response: The research was prompted by the rise of Candida auris (C. auris) as a critical fungal pathogen that has caused global outbreaks in healthcare facilities with high mortality rates. C. auris is particularly difficult to control because it can survive on physical surfaces for extended periods. Current diagnostic methods (such as culture-based approaches or mass spectrometry) are often costly, slow, and require complex equipment in centralized laboratories, which delays effective clinical responses. There is an urgent need for rapid tests that can both identify the fungus and measure its level of drug resistance.
Author Interviews, Infections / 05.02.2025

MedicalResearch.com Interview with: [caption id="attachment_66392" align="alignleft" width="200"]Prof. Vishnu Chaturvedi, Ph.D., HCLDDepartment of Pathology, Microbiology and Immunology New York Medical College Department of Pathology, Westchester Medical Center Valhalla, New York Prof. Chaturvedi[/caption] Prof. Vishnu Chaturvedi, Ph.D., HCLD Department of Pathology, Microbiology and Immunology New York Medical College Department of Pathology, Westchester Medical Center Valhalla, New York, MedicalResearch.com: What is the background for this study? How does Candida auris differ from Candida albicans, ie in clinical presentation or treatment?    
  1. Candida aurisis a newly discovered yeast that is considered a global health threat by the CDC and WHO. The sudden emergence and rapid spread of this multidrug-resistant pathogen is being explained by several published hypotheses. These include global warming, salt water tolerance, or agriculture use of fungicides as plausible causes. In the US, the NY-NJ metropolitan area was the first to suffer from drug-resistant Candia auris clade I genotype. None of the earlier hypotheses could explain the appearance in NY-NJ. Here, we set out to answer two related questions: “why NY-NJ?” and “why clade I?”
  2. Candida albicansis a well-known commensal yeast that frequents human mucosal surfaces in the mouth, vagina, etc. In contrast, Candida auris is a newly discovered yeast that colonizes the skin of hospitalized patients and long-term care residents. A small subset of those colonized develop Candida auris bloodstream and deep tissue infections.
  3. Candida auris differs from  albicans in its ability to cause healthcare-associated infection outbreaks. Candida auris is also prone to rapid acquisition of the resistance of multiple antifungal drugs. Finally, C. auris bloodstream infections cause high mortality.
Thank you for visiting MedicalResearch.com Senior Editor, Marie Benz MD. For more information please email: info@MedicalResearch.com

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.